Pharmaceutical

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Jun 3, 2025 - 06:00
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.
Read the original article

Tags:

Previous Article

ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups

Next Article

CirCode Biomed gains clearance from FDA for RNA drug HM2002

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ActiGraph executives on why getting digital endpoints approved for drug trials matters

STAT+: ActiGraph executives on why getting digital endp...

Aug 17, 2023

STAT+: Why FDA product recalls have spiked in recent years

STAT+: Why FDA product recalls have spiked in recent years

Dec 15, 2023

Agilent agrees to acquire BIOVECTRA for $925m

Agilent agrees to acquire BIOVECTRA for $925m

Jul 24, 2024